# Cytokinetics, Incorporated (CYTK)

> Source: Nexqual · https://nexqual.com/CYTK · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Cytokinetics, Incorporated (CYTK), nexqual.com/CYTK" · informational, not investment advice.

**Price:** USD 62.33 (-0.84% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 62.86 · day 61.94–64.07 · 52w 54.3–88.31 · market cap $8.67B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $67.7M, net income -$894M (-1321.1% margin), free cash flow -$581M (SEC filings).
- Insider open-market sales, last ~7 months: 45 Form 4 filings, $33.1M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 27 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y +8.4% vs S&P 500 +14.9%; 5Y +68.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD -1.41, revenue estimate $41.6M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $70.4M | $94.6M | $7.5M | $18.5M | $88.0M | $67.7M |
| Operating income | -$186M | -$324M | -$496M | -$536M | -$612M | -$708M |
| Net income | -$215M | -$389M | -$526M | -$590M | -$785M | -$894M |
| EPS (diluted) | -$2.80 | -$4.33 | -$5.45 | -$5.26 | -$6.54 | — |
| Free cash flow | -$191M | -$311M | -$416M | -$400M | -$535M | -$581M |
| Operating margin | -264.5% | -342.8% | -6589.7% | -2902.7% | -695.4% | -1046.1% |
| Net margin | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% | -1321.1% |
| Revenue growth | +26.2% | +34.3% | -92.0% | +145.3% | +376.6% | — |
| Cash + short-term investments | $624M | $829M | $655M | $1.20B | $1.20B | — |
| Total debt | $47.4M | $650M | $639M | $620M | $288M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 128.1x · EV/Sales 107.0x · FCF yield -6.70% · Earnings yield -10.32% · Net cash $1.42B · EV $7.24B

## Insider sales (SEC Form 4, open-market, last ~7 months)
45 of 45 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Malik Fady Ibraham | EVP Research & Development | 3,500 | $224K | 2.2% | Yes | Routine (sold in Jan & Feb & Mar & Apr & May & Jun & Jul & Aug & Sep & Oct & Nov each year 2023–2025) |
| 2026-10-12 | Blum Robert I | President & CEO | 7,500 | $472K | 2.6% | Yes | Routine (sold in Jun & Jul & Aug & Sep & Oct each year 2023–2025) |
| 2026-10-06 | Malik Fady Ibraham | EVP Research & Development | 3,500 | $215K | 2.2% | Yes | Routine (sold in Jan & Feb & Mar & Apr & May & Jun & Jul & Aug & Sep & Oct & Nov each year 2023–2025) |
| 2026-09-28 | Blum Robert I | President & CEO | 7,500 | $491K | 2.6% | Yes | Routine (sold in Jun & Jul & Aug & Sep & Oct each year 2023–2025) |
| 2026-09-22 | Malik Fady Ibraham | EVP Research & Development | 3,500 | $239K | 2.2% | Yes | Routine (sold in Jan & Feb & Mar & Apr & May & Jun & Jul & Aug & Sep & Oct & Nov each year 2023–2025) |
| 2026-09-15 | Landry Robert E | Director | 1,000 | $72K | 10.9% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-14…2026-09-15 | Blum Robert I | President & CEO | 105,426 | $7.3M | 27.2% | Yes | Routine (sold in Jun & Jul & Aug & Sep & Oct each year 2023–2025) |
| 2026-09-11 | Landry Robert E | Director | 1,000 | $75K | 9.8% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-08 | Malik Fady Ibraham | EVP Research & Development | 3,500 | $264K | 2.2% | Yes | Routine (sold in Jan & Feb & Mar & Apr & May & Jun & Jul & Aug & Sep & Oct & Nov each year 2023–2025) |
| 2026-09-01 | Parshall B Lynne | Director | 5,000 | $357K | 31.7% | Yes | Too little history (no open-market trades in 2023) |
| 2026-08-31 | Callos Andrew | EVP, Chief Commercial Officer | 10,000 | $702K | 14.6% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-31 | Blum Robert I | President & CEO | 7,500 | $527K | 1.9% | Yes | Routine (sold in Jun & Jul & Aug & Sep & Oct each year 2023–2025) |
| 2026-08-18 | Malik Fady Ibraham | EVP Research & Development | 3,500 | $265K | 2.2% | Yes | Routine (sold in Jan & Feb & Mar & Apr & May & Jun & Jul & Aug & Sep & Oct & Nov each year 2023–2025) |
| 2026-08-10 | Blum Robert I | President & CEO | 7,500 | $576K | 1.9% | Yes | Routine (sold in Jun & Jul & Aug & Sep & Oct each year 2023–2025) |
| 2026-07-30 | Callos Andrew | EVP, Chief Commercial Officer | 14,000 | $1.1M | 19.3% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-27 | Blum Robert I | President & CEO | 7,500 | $607K | 1.9% | Yes | Routine (sold in Jun & Jul & Aug & Sep & Oct each year 2023–2025) |
| 2026-07-21 | Malik Fady Ibraham | EVP Research & Development | 3,500 | $282K | 2.2% | Yes | Routine (sold in Jan & Feb & Mar & Apr & May & Jun & Jul & Aug & Sep & Oct & Nov each year 2023–2025) |
| 2026-07-13 | Blum Robert I | President & CEO | 7,500 | $615K | 1.9% | Yes | Routine (sold in Jun & Jul & Aug & Sep & Oct each year 2023–2025) |
| 2026-07-07 | Malik Fady Ibraham | EVP Research & Development | 3,500 | $303K | 2.2% | Yes | Routine (sold in Jan & Feb & Mar & Apr & May & Jun & Jul & Aug & Sep & Oct & Nov each year 2023–2025) |
| 2026-07-01 | Blum Robert I | President & CEO | 7,500 | $637K | 1.9% | Yes | Routine (sold in Jun & Jul & Aug & Sep & Oct each year 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | HC Wainwright & Co. | Reiterated | Buy | $140 |
| 2026-10-16 | William Blair | Initiated | Outperform |  |
| 2026-10-08 | RBC Capital | Target raised | Outperform | $112 → $113 |
| 2026-08-31 | HC Wainwright & Co. | Reiterated | Buy | $140 |
| 2026-08-13 | Barclays | Target raised | Overweight | $95 → $110 |
| 2026-08-13 | JP Morgan | Target raised | Overweight | $97 → $103 |
| 2026-08-10 | Truist Securities | Target raised | Buy | $106 → $112 |
| 2026-08-07 | RBC Capital | Target lowered | Outperform | $117 → $112 |
| 2026-08-07 | Citizens | Target raised | Market Outperform | $105 → $110 |
| 2026-08-07 | Needham | Target raised | Buy | $102 → $112 |
| 2026-07-07 | RBC Capital | Target lowered | Outperform | $119 → $117 |
| 2026-06-29 | UBS | Upgrade | Neutral → Buy | $69 → $115 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +8.4% | +68.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +8.4% | +10.9% |
| Volatility (annualized) | 42.1% | 59.3% |
| Max drawdown | -30.0% (Jun 2026→Oct 2026) | -67.4% (Jan 2024→May 2025) |

## Peers (Biotechnology)
SYRE (Spyre Therapeutics, Inc.) USD 92.33 -0.67% · PTGX (Protagonist Therapeutics, Inc.) USD 139.53 +1.05% · CAI (Caris Life Sciences, Inc.) USD 31.71 -1.98% · IBRX (ImmunityBio, Inc.) USD 8.31 -3.82% · ARWR (Arrowhead Pharmaceuticals, Inc.) USD 58.36 -0.82% · KYMR (Kymera Therapeutics, Inc.) USD 110.85 -1.58%

## More
Full page: https://nexqual.com/CYTK · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in CYTK's own 10-K filed 2026-02-26 (https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Bayer | "Under the terms of our license and collaboration agreements, Sanofi is responsible for the development and commercialization of aficamten (to be commercialized as MYQORZO) in China and Bayer is responsible for the develo…" |
| Partner | Royalty Pharma Development Funding | "Concurrently, we entered into a common stock purchase agreement with RPFT through which RPFT purchased 875,656 shares of the Company's common stock for $10.0 million." |
| Competitor | Merck (MRK) | "Omecamtiv mecarbil could also compete against other novel drug candidates and therapies in development, such as those being developed by Novartis AG, Merck & Co., Inc., Bayer AG, AstraZeneca PLC, Kardigan, Inc., and Bris…" |
| Competitor | Eli Lilly (LLY) | "Therefore, ulacamten could also compete against other novel drug candidates and therapies in development, such as those being developed by Eli Lilly, Novo Nordisk, Mission Therapeutics, Cardurion Pharmaceuticals and pote…" |
| Competitor | Novo Nordisk (NVO) | "Therefore, ulacamten could also compete against other novel drug candidates and therapies in development, such as those being developed by Eli Lilly, Novo Nordisk, Mission Therapeutics, Cardurion Pharmaceuticals and pote…" |

Other companies that name CYTK in their own reports (relationship from CYTK's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Royalty Pharma plc (RPRX) | 10-K 2026-02-11 | "In May 2024, we expanded our funding collaboration with Cytokinetics, Incorporated ("Cytokinetics")." |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Net Product Revenue | $25.3M | 88.5% | — |
| Collaboration Revenues | $3.3M | 11.5% | +36.2% |
| Total revenue | $28.6M | 100% | — |

## Customer concentration

Period ended 2026-06-30: 36%, 34%, 23% of revenue from unnamed direct customers (10-Q, filed 2026-08-06).

## Company outlook (8-K filed 2026-08-06)

- "The financial guidance does not include the effect of GAAP adjustments as may be caused by events that occur subsequent to publication of this guidance including, but not limited to, Business Development activities."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-1.41 | $-1.55 | -8.8% | $41.6M | 17 |
| Next quarter (ends 2026-12-31) | $-1.39 | $-1.50 | -7.5% | $61.2M | 17 |
| Current fiscal year (ends 2026-12-31) | $-5.87 | $-6.32 | -7.1% | $156.3M | 17 |
| Next fiscal year (ends 2027-12-31) | $-4.46 | $-4.68 | -4.9% | $428.6M | 17 |